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Chronic immune-mediated diseases of adulthood often originate in early childhood. To
investigate genetic associations between neonatal immunity and disease, we map expression
quantitative trait loci (eQTLs) in resting myeloid cells and CD4+ T cells from cord blood
samples, as well as in response to lipopolysaccharide (LPS) or phytohemagglutinin (PHA)
stimulation, respectively. Cis-eQTLs are largely specific to cell type or stimulation, and 31%
and 52% of genes with cis-eQTLs have response eQTLs (reQTLs) in myeloid cells and T cells,
respectively. We identified cis regulatory factors acting as mediators of trans effects. There is
extensive colocalisation between condition-specific neonatal cis-eQTLs and variants asso-
ciated with immune-mediated diseases, in particular CTSH had widespread colocalisation
across diseases. Mendelian randomisation shows causal neonatal gene expression effects on
disease risk for BTN3A2, HLA-C and others. Our study elucidates the genetics of gene
expression in neonatal immune cells, and aetiological origins of autoimmune and allergic
diseases.
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Infancy is a critical period during which physiological anddevelopmental changes impact the pathogenesis of conditionslater in life1,2. Many complex diseases, in particular immune
and respiratory conditions, are partially determined by genetic
predisposition and early-life environment exposures, such as
microbes or allergens3–5. Yet, despite increasing evidence of its
importance, little is known about the early-life genetic regulation
of gene expression, nor its relevance to predisposition for diseases
in adulthood.
Expression quantitative trait loci (eQTL) studies have provided
insights into the gene regulatory effects of genetic variants and
their relationship with complex disease6,7. The majority of eQTLs
have been identified in adult tissues, while eQTLs in perinatal
tissues have only been explored recently: for example, eQTLs
identified in foetal placentas8 and foetal brains9 are enriched for
genetic variants associated with growth (e.g. adult height) and
neuropsychiatric (e.g. schizophrenia) traits, respectively. In
addition to genetic variation, disease development is influenced
by individual and cell-type-specific responses to external stimuli.
Understanding the interaction between eQTLs and these stimuli
can give insights into condition(s), whether they be cell type,
microbe or temperature, under which genetic variants may
influence disease. Previous studies have investigated response
eQTLs (reQTLs), eQTLs with genetic effects modified by external
stimulation, in CD14+ monocytes10,11, macrophages12, dendritic
cells13,14, and CD4+ T cells15. However, reQTL studies to date
have been largely performed using adult samples, and we cur-
rently have limited knowledge of how neonatal immune gene
expression is regulated in response to stimuli.
Here, we characterise the genetics of gene expression in the
innate and adaptive arms of the neonatal immune system using
purified cord blood samples from 152 neonates16–18. In these
samples, we identify cis- and trans-eQTLs of myeloid cells and
CD4+ T cells, as well as reQTLs for myeloid cells stimulated with
lipopolysaccharide (LPS; a component of bacterial cell walls) and
CD4+ T cells stimulated with phytohemagglutinin (PHA; a pan-T
cell mitogen). By comparing our neonatal cis-eQTLs with pre-
viously identified adult eQTLs, we find eQTLs that are specific to
neonates. Using mediation analysis, instances of putative trans
gene regulation are investigated to identify cis regulatory
mechanisms. We show evidence for the shared genetic basis of
neonatal eQTLs and reQTLs with common autoimmune and
allergic diseases, and many of such colocalisations are cell type- or
stimulation-specific. Finally, we use Mendelian randomisation to
uncover the causal effects of neonatal gene expression on risk of
immune-mediated diseases. Ultimately, we highlight the potential
importance of the perinatal period in understanding the origins of
immune-mediated disease.
Results
Genetics of neonatal gene expression in innate and adaptive
immunity. We performed eQTL analysis on cell preparations
derived from in vitro cultures of resting and stimulated neonatal
immune cells from 152 neonates of the Childhood Asthma Study
(CAS) cohort (Fig. 1), which were enriched respectively for non-
adherent T cells and adherent myeloid cells as detailed in
‘Methods’, with the latter largely being monocytes and macro-
phages. Cell purities could not be experimentally confirmed by
flow cytometry due to limited blood volumes that could be col-
lected from neonates; rather, in silico analyses were utilised to
estimate the abundances of relevant cell types using CIBER-
SORTx19. These analyses indicated dominance of the relevant T-
cell and myeloid signatures (Supplementary Fig. 1). Among 135
genotyped individuals, 106 and 119 had gene expression data
passing QC for both resting and stimulated conditions of myeloid
and T-cell cultures, respectively, and 95 individuals had post-QC
data for all four cultures. The total number of samples available
for eQTL analysis was 116 for resting myeloid cells, 125 for LPS-
stimulated myeloid cells, 126 for resting T cells, and 127 for PHA-
stimulated T cells.
To identify cis-eQTLs, we applied a hierarchical procedure to
correct for multiple testing within each experimental condition at
5% false discovery rate (FDR; ‘Methods’). Stimulated cells yielded
a larger number of cis-eQTLs and associated genes (eGenes) than
resting cells (1347 vs. 971 eGenes in PHA-stimulated vs. resting
T cells, respectively; 376 vs. 136 in LPS-stimulated vs. resting
myeloid cells, respectively; Fig. 2a, Supplementary Data 1). To
investigate the differences in numbers of eGenes between
conditions, we repeated the analysis controlling for differences
in sample size (randomly sampling 116 samples in each
condition). This yielded similar results to the numerical
distribution of cis-eGenes: 1231, 900, and 350 in PHA-
stimulated T cells, resting T cells, and LPS-stimulated myeloid
cells, respectively. The lower number of eQTLs in myeloid cells
may be explained by fewer genes being expressed (Supplementary
Fig. 2).
For eGenes with eQTLs in multiple experimental conditions,
we performed conditional analysis to distinguish whether these
were independent or shared signals between conditions (‘Meth-
ods’). The majority (74%) of eQTL signals were specific to one
cell type or stimulatory condition (Supplementary Fig. 3A),
consistent with previous observations10. About 10–50% of the
condition-specific signals were replicated using a multivariate
adaptive shrinkage (mash) model (Supplementary Fig. 3B)20. We
observed a majority of cis-eQTL effects after stimulation: 60%
(262 of 376) of eGenes in LPS-stimulated myeloid cells and 58%
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Cord blood PBMCs
(N = 152)
Genotyping
(N = 135)
Imputation
Association test
Gene expression profiling
Response eQTLs
eQTLs
Myeloid cells T cells
At birth
Genetic variants for
diseases in adulthood
Genetic regulatory
variants in early life
• Colocalisation with disease associations
• Causal evaluation of gene expression
GWAS summary statistics
I
V X Y
U
?
LPS PHA
Resting
Fig. 1 Study design and analysis work flow. Monocyte/macrophage-
enriched cultures (myeloid cells) and T-cell-enriched cultures were
extracted from resting and stimulated cord blood samples from the
Childhood Asthma Study (CAS) cohort. Gene expression was quantified
using a microarray platform. Genotype data are available for a subset of the
CAS individuals. eQTLs were identified within each experimental condition.
Datasets for resting and stimulated samples were merged to detect
response eQTLs within each cell type. Next, we identified genetic loci
where neonatal eQTLs and disease associations obtained from external
GWAS datasets shared the same causal variants. We investigated the
causal effects of gene expression at birth on immune diseases that develop
later in life.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17477-x
2 NATURE COMMUNICATIONS |         (2020) 11:3761 | https://doi.org/10.1038/s41467-020-17477-x | www.nature.com/naturecommunications
(778 of 1347) in PHA-stimulated T cells. Using a two-step
conditional analysis (‘Methods’), PHA-stimulated T cells had
the largest number of eGenes (6.3%; Supplementary Table 1)
with multiple independent eQTL signals. GARFIELD
enrichment analysis21 showed that the cis-eSNPs were enriched
in 3′ untranslated regions (UTR), 5′ UTR, and exon regions
(Supplementary Fig. 4), consistent with known mechanisms of
cis-eQTLs.
We compared our resting and LPS-stimulated myeloid cells
with those from adults in Kim-Hellmuth et al.11 using the mash
model20. We found that 6.7% and 7.2% of the cis-eQTLs tested in
both studies (105 and 332 eQTLs) were specific to neonates at
LFSR of 0.05 (Fig. 2b). Similarly, we compared resting neonatal
T cells to adult T cells of the BLUEPRINT project22: after
excluding 332 cis-eQTLs that were not tested in the adult T cells,
we found that 24.7% neonatal cis-eQTLs were not active in adult
T cells. We have also used the Storey and Tibshirani q-value
approach23 to investigate eQTL sharing between neonatal and
adult tissues. Replication rate quantified by π1 statistic was 0.998
for resting myeloid cells, 0.987 and 0.947 for LPS-stimulated
myeloid cells comparing to monocytes treated by LPS for 90 min
and 6 h, respectively, in Kim-Hellmuth et al., and 0.879 for resting
T cells. We note, however, that this approach may overestimate
the replication rate as it does not take the direction or magnitude
of eQTL effects into account.
Genetics of neonatal gene expression in response to stimuli. To
quantify how genetic regulation of gene expression is altered by
external stimuli, we identified response eQTLs (reQTLs) and
response eGenes (reGenes) by performing interaction tests on the
top eSNPs of each eGene in myeloid cells and T cells separately,
and controlling FDR at 5% using permutation-determined P-
values (‘Methods’). In myeloid cells, we identified 125 significant
reQTLs involving 125 unique reGenes (31% of 398 myeloid
eGenes); in T cells, we identified 956 reQTLs involving 918
unique reGenes (52% of 1749 T cell eGenes), among which 38
reGenes had distinct cis-eQTLs in two conditions where both
eQTLs were reQTLs (Supplementary Data 2). Consistent with our
findings for cis eQTLs and eGenes, the number of reQTLs and
proportion of reGenes were greater in stimulated compared to
resting conditions.
For two reQTLs, the direction of eQTL effect changed between
conditions (Fig. 2c). The C allele of the top eSNP (rs5751775) for
DDT (D-dopachrome tautomerase), a gene functionally related to
the inflammatory cytokine MIF (migration inhibitory factor),
increased DDT transcription in resting T cells but decreased
expression after PHA stimulation (Supplementary Fig. 5A,
Supplementary Data 2). Similarly, the T allele of the top eSNP
(rs13068288) for ZNF589 increased transcription of ZNF589 in
resting T cells but reduced expression after PHA stimulation
(Supplementary Fig. 5B, Supplementary Data 2).
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Fig. 2 Cis-eQTLs and response eQTLs (reQTLs) in myeloid cells and T cells. a A bar plot shows the number of genes with significant cis-eQTLs (eGenes)
at a 5% false discovery rate (FDR) identified in each cell type and treatment group (on x-axis). Percentages on each bar indicate the proportion of eGenes
with significant reQTLs at 5% FDR (‘Methods’). b Three pie charts show the proportions of eQTLs that were specific to neonates in resting myeloid cells
(n= 116 biologically independent samples), LPS-stimulated myeloid cells (n= 125), and resting T cells (n= 126), respectively. Neonatal specific eQTLs
were defined by comparing the eQTLs in our study with that identified in resting and LPS-stimulated (90min or 6 h) monocytes obtained from adults (Kim-
Hellmuth et al.11, n= 134), and that in naïve adult T cells (BLUEPRINT project22, n= 125; ‘Methods’). Myeloid eQTLs that were not tested in the Kim-
Hellmuth et al. study (31 and 44 in resting and stimulated conditions, respectively) or T-cell eQTLs that were not tested in the Chen et al. study (332 in
resting T cells) were excluded in the analysis. c Two point plots show effect sizes (difference in gene expression in s.d. per allele) of significant reQTLs in
resting (x-axes) and stimulated conditions (y-axes) in two cell populations: myeloid cells (left) and T cells (right). A gene might have two dots indicating
two independent top SNPs (‘Methods’). Colours indicate the condition in which the SNP was significant. ReQTLs of DDT and ZNF585 in the grey quadrants
(red dots) show opposite directions of eQTL effects across conditions.
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Disentangling trans and cis effects using mediation analysis.
While we were relatively underpowered to detect trans-eQTLs, we
maintained stringent significance thresholds and compared
overlapping cis and trans effects to generate hypotheses of gene
regulation (‘Methods’). We identified 25 trans-eQTLs in T cells
(10 in resting, 15 in PHA-stimulated), and one trans-eQTL in
myeloid cells (Fig. 3a, Supplementary Data 3) at a genome-wide
FDR of 5%. Notably, the trans-eQTL forMYH10, a component of
myosin heavy chain which regulates cytokinesis, was shared
across all four experimental conditions; furthermore, the same
eQTL was associated with multiple trans-eGenes in T cells:
MIR130A and STX1B in resting and stimulated T cells, and IP6K2
and MIR1471 in resting T cells only (Fig. 3a).
Consistent with previous reports that trans-eQTLs are enriched
for cis-eQTLs24, we found that multiple trans-eQTLs (the single
trans-eQTL in myeloid cells, 6 of the 10 in resting T cells, and 3 of
the 15 in PHA-stimulated T cells) were significantly associated
with local genes in cis (Fig. 3a, Supplementary Data 3). The trans-
eQTL for MYH10 was also a cis-eQTL for RPS26 (part of the 40S
subunit of the ribosome) in all conditions except PHA-stimulated
T cells. The top eSNP (rs1131017) for RPS26, located in its 5’
UTR, was also a cis-eQTL for SUOX (sulphite oxidase, a
homodimer in the intermembrane space of mitochondria) in
resting and stimulated T cells. Separately, the trans-eQTL
(rs687492) for microRNA MIR330 was also a cis-eQTL for the
long non-coding RNA SNHG8 in resting and stimulated T cells.
Mediation analysis revealed that the trans-eQTL effects of
rs687492 on MIR330 were cis mediated through SNHG8 (Fig. 3b,
c, Supplementary Table 2; ‘Methods’), indicating a potential
pathway containing this lncRNA-miRNA cross-talk. Further-
more, mediation analysis also revealed the regulatory logic of cis-
eQTL (rs1131017) for SUOX and RPS26, identifying that its
trans-effects on MYH10, MIR130A, and IP6K2 were mediated
through RPS26 and not SUOX in resting T cells (Fig. 3d,
Supplementary Table 2).
Genetic overlap with immune-mediated diseases. To investigate
the genetic overlap between neonatal gene expression and disease,
we used a multi-pronged approach. First, we performed GAR-
FIELD enrichment analyses to test for significant overlaps
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Fig. 3 Trans-eQTL effects and their cis-mediators. a A circular plot shows trans-eQTL associations in lines, with arrows pointing to trans-eGenes with
names annotated (in black) outside the rim indicating chromosome numbers. Dots on the other end point indicate nearby genes (names in purple) that are
associated with the same loci (cis-eQTLs). Colours of the lines indicate the experimental conditions where the trans-eQTLs were identified: resting T cells
only (Resting T), stimulated T cells only (PHA T), shared between both conditions of T cells (Resting T & PHA T), and shared across all four experimental
conditions (All four conditions). b A diagram demonstrates the mediation analysis model, where effects of trans-acting eQTL (exposure) on trans-eGene
(outcome) are either mediated through a cis-eGene (mediator), or through direct effects (‘Methods’). c, d Show two examples of cis-eGenes (green),
SNHG8 and RPS26, acting as mediators for trans-effects (trans-eGenes in yellow). Genes that were not significant in mediation analysis are in grey. Tables
show statistics of the mediation tests, and the column named Mediation indicates the proportion of total effects of the eQTL on the trans-eGene that was
mediated through the cis-eGene. Two models involving SUOX (d) were not tested because the trans-eSNPs of IP6K2 and MIR1471 were not significantly
associated with SUOX (Supplementary Data 3). Significant mediations (FDR≤ 0.05) are highlighted in bold.
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between the cis-eQTLs and variants associated with immune-
mediated diseases in genome-wide association studies (GWAS;
‘Methods’). We found widespread enrichment amongst cis-eQTLs
for genetic variants associated with diseases such as allergic dis-
ease (asthma, hay fever, or eczema) and inflammatory bowel
disease. Conversely, same analysis with non-immune-related
traits such as educational attainment identified limited enrich-
ment (Supplementary Fig. 6). Specifically, we did not observe
significant enrichment of GWAS signals for educational attain-
ment in myeloid eQTLs; there was evidence of enrichment in
resting and PHA-stimulated T cells but enrichment was not as
strong (effect sizes 0.43 and 0.52 respectively) compared to
immune-mediated diseases (ranging from 1.13 to 7.37).
Second, we performed colocalisation analysis25 to identify
variants sharing regulatory (eQTL) and disease-associated
(GWAS) signals (‘Methods’). In total, we observed 68 colocalisa-
tions, involving 5, 9, 15, and 17 independent cis-eQTLs in resting
myeloid cells, LPS-stimulated myeloid cells, resting T cells, and
PHA-stimulated T cells, respectively (Fig. 4a, Supplementary
Data 4). Our analysis replicated the colocalisation of the cis-eQTL
for BACH2 in resting T cells with variants for type 1 diabetes22,
and also revealed widespread colocalisation with autoimmune
thyroid disease, celiac disease, multiple sclerosis, rheumatoid
arthritis (Supplementary Fig. 7). BACH2 encodes a transcrip-
tional repressor that restrains terminal differentiation and
promotes the development of memory lymphocytes including
CD8+ T cells26 and B cells27. At the BACH2 locus, the A allele at
the top eSNP (rs72928038) was associated with decreased BACH2
expression and increased risk of the above diseases. This was
consistent with previous studies which showed that mutations
and loss-of-function variants of BACH2 resulted in immunode-
ficiency and disruption to regulatory T cell function, with
subsequent autoimmunity28,29.
We found 17 colocalisations of reQTLs and disease variants, in
total involving 12 reQTLs: one myeloid reQTL specific to LPS
stimulation (eQTL for CTSH), and 11 reQTLs in T cells, among
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Fig. 4 Colocalisation of cis-eQTLs with disease associations. a A heatmap shows all cases with strong evidence of colocalisation between cis-eQTLs of
corresponding genes (eGenes) in rows and GWAS hits associated with allergic and autoimmune diseases in columns (ic: the study was performed using
ImmunoChip array). Colours indicate the cell type where the significant colocalisation was observed. Asterisks indicate that the colocalised eQTLs are
response eQTLs (reQTLs). b Boxplots show the rank-normalised gene expression of IL13 (y-axes) in resting T cells (left) and in PHA-stimulated T cells
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which eight were specific to PHA stimulation. Notably, the reQTL
for IL13 in PHA-stimulated T cells colocalised with GWAS hits
associated with asthma, allergic sensitisation, and allergic disease
(Fig. 4, Supplementary Data 4). The T allele of the top eSNP
(rs1295686) was associated with greater IL13 expression in PHA-
stimulated T cells as well as increased risk of all three diseases
(Fig. 4b). rs1295686 is intronic to IL13 and in strong LD (r2 >
0.98) with four other eSNPs, including a Gln144Arg missense
SNP (rs20541) in IL13. At the CCL20 locus, the A allele of the cis-
eQTL/reQTL (rs13034664) in PHA-stimulated T cells was
associated with lower CCL20 expression as well as increased risk
of childhood-onset asthma (Fig. 4a, Supplementary Fig. 8,
Supplementary Data 4). CCL20 is part of the CCR6-CCL20
receptor-ligand axis, a key driver of dendritic cell chemotaxis30.
Our analyses uncovered complex condition-specific colocalisa-
tions at multiple loci. The ubiquitin ligand UBASH3A, known to
regulate apoptosis in T cells, had two independent cis-eQTLs in
resting and stimulated T cells which were also reQTLs. However,
only the cis-eQTL in resting T cells (rs1893592) colocalised with
celiac disease, rheumatoid arthritis, and primary sclerosing
cholangitis (PSC; Fig. 4, Supplementary Data 4). Cis-eQTLs for
CTSH, which encodes the lysosomal cysteine proteinase cathepsin
H, colocalised with signals for different diseases in a cell type- and
condition-specific manner (Supplementary Fig. 9, Supplementary
Data 4). Cis-eQTLs for CTSH in resting myeloid cells and resting
T cells both colocalised with GWAS hits for celiac disease,
narcolepsy, and type 1 diabetes, which has been observed in
immune cell types from adults: colocalisation with causal variants
of celiac disease and narcolepsy was reported in macrophages12,
and type 1 diabetes in adult monocytes22. On the other hand, cis-
eQTLs for CTSH in LPS-stimulated myeloid cells and PHA-
stimulated T cells both colocalised with primary biliary
cirrhosis (PBC).
Causal effects of condition-specific gene expression on
immune-mediated diseases. To identify putative causal effects of
neonatal gene expression on risk of autoimmune and allergic
disease, we performed two-sample Mendelian randomisation
(MR) analysis using cis-eQTLs as genetic instruments, the neo-
natal cis-eGene as exposure, and disease as outcome (‘Methods’).
We tested the 52 eGenes which had three or more genetic
instruments available, and the diseases above, for which we had
GWAS summary statistics available. We considered genes for
which at least three of four MR methods (inverse variance
weighted, weighted median, weighted mode, and MR Egger) were
in agreement in detecting significant causal effects (P-value ≤
0.05) on a disease without significant pleiotropic effects (Sup-
plementary Data 5).
In our MR analysis, we found multiple conditions where
neonatal gene expression had a causal effect on multiple diseases
(Fig. 5), including BTN3A2 (butyrophilin subfamily 3 member
A2), HLA-C (major histocompatibility complex class I molecule),
MICB (ligand for an activatory receptor expressed on natural
killer cells, CD8+ αβ T cells, and γδ T cells), ZNRD1 (RNA
polymerase 1 subunit), and SLC22A5 (carnitine transporter)
(Supplementary Data 5). BTN3A2 had a relatively large number
of genetic instruments for resting (seven to eight) and stimulated
(three to five) T cells, and the causal estimates were similar
between these two conditions (Supplementary Figs. 10, 11). In
resting T cells, increased expression of BTN3A2 was causally
associated with decreased risk of asthma (weighted mode causal
estimate=−0.056 log odds decrease per s.d. increase in
BTN3A2), both childhood- and adult-onset asthma (−0.047 and
−0.039, respectively), allergic rhinitis (−0.044), PSC (−0.440),
and systemic lupus erythematosus (SLE; −0.256). Conversely,
increased BTN3A2 expression was associated with increased risk
of inflammatory bowel disease (IBD; 0.025), including Crohn’s
disease (0.053), as well as risk of PBC (0.129), where PBC variants
also showed colocalisation with BTN3A2 eQTLs (Fig. 4, Supple-
mentary Fig. 12). Expression of HLA-C in T cells showed strong
causal association with autoimmunity, in particular positive
causal effects on psoriasis, SLE, PSC, multiple sclerosis, IBD, and
ulcerative colitis; and negative causal effects on juvenile idiopathic
arthritis, PBC, and rheumatoid arthritis (Fig. 5, Supplementary
Figs. 13, 14).
Discussion
In this study, we investigated the genetic regulation of gene
expression in cells of neonatal innate and adaptive immunity, and
its relationship to the genetic basis of autoimmune and allergic
diseases. In this context, we illustrated that the genetics of gene
expression in neonates is strongly specific to cell type and sti-
mulatory condition, and is distinct from that of adults. We
described regulatory mechanisms of eQTLs whose putative trans
effects had evidence of mediation via gene expression in cis. In
exploring the potential early-life origins of disease, our analyses
showed an extensive genetic overlap of genetic variants associated
with immune-mediated diseases and those with effects on gene
expression in neonatal immune cells. Finally, Mendelian rando-
misation showed that myriad changes in gene expression at birth
had potentially causal effects on autoimmune and allergic
disease risk.
We observed stimuli changing the direction of eQTL effects in
resting and PHA-stimulated T cells. This was the case for the C
allele of reQTL (rs5751775) and DDT, a cytokine structurally and
functionally related to MIF, a critical regulator of both innate and
the adaptive immune response31. It is known that eQTL effects
can change direction in immune cells32. In the Genotype-Tissue
Expression (GTEx) Project6, the direction of eQTL effect for the
C allele at rs5751775 was also variable across liver, pancreas,
stomach, testis, brain, and muscle tissues, though the variable
direction of eQTL effect may also be due to LD contamination,
i.e. when the top eSNPs tag two distinct eQTLs in two conditions.
Our results suggest a trans mediation role for RPS26, rather
than SUOX, consistent with previous studies linking RPS26 to
IP6K233,34. RPS26 and SUOX were both identified as significant
mediators in multiple tissues in the GTEx dataset; however,
within the same tissue, the trans-associations mediated
through SUOX were not identical to those through RPS26, indi-
cating distinct effects of SUOX and RPS26 on distant genes34.
RPS26 encodes a ribosomal subunit protein which, apart from its
role in ribosome assembly and translation35, is involved in var-
ious other cellular processes, including nonsense-mediated
mRNA decay36 and p53 transcriptional activity37. It is likely
that the broad trans effects of RPS26 may be related to its ribo-
somal functions.
At the CCL20 locus, the reQTL (rs13034664) in PHA-
stimulated T cells colocalised with childhood-onset asthma
(Fig. 4a, Supplementary Fig. 8). CCL20 encodes a C–C chemokine
ligand that binds to a G protein-coupled receptor, and elevated
CCL20 expression has been shown in airways of patients with
chronic obstructive pulmonary disease (COPD)38 and asthma39.
CCL20 induces mucin production by binding to its unique
receptor (CCR6) in human airway epithelial cells40. However, in
PHA-stimulated T cells, the A allele of the reQTL (rs13034664),
which was linked to increased risk of childhood-onset asthma,
was associated with reduced CCL20 expression (Supplementary
Fig. 8B). This reQTL and its direction of effect were replicated by
others in activated CD4+ T cells7. T cells themselves respond to
CCL20 via binding to CCR6, and this process is observed during
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allergen provocation41. It is possible that the pathophysiological
mechanism is not T cell production of CCL20, but rather their
response to it – hence the reduced CCL20 expression in a possible
feedback loop. Altogether, these findings reinforce the cell-type-
specific nature of eQTL and reQTL associations.
On the other hand, the reQTL for IL13 in neonatal PHA-
stimulated T cells appeared to share causal variants with allergic
disease and asthma, suggesting that this reQTL may affect allergic
disease risk via mechanisms that do involve T cell activation and
interleukin 13 (IL-13). PHA is a pan-T cell mitogen, and down-
stream intracellular signalling may be shared between PHA and
allergen-mediated T cell activation. IL-13 is produced by activated
CD4+ and CD8+ T cells42 among others, promoting immu-
noglobulin E (IgE) production in B cells43. IL-13 has been shown
to induce asthma symptoms including airway hyper-responsive-
ness, increased total serum IgE, and increased mucus production
in murine models44. Increased IL-13 expression is observed in
sputum and bronchial biopsy in mild45 and severe46 asthma and
can serve as a biomarker for severe refractory asthma47. Therapies
that target IL-13 (anti-IL-13 antibodies) have been developed,
such as lebrikizumab and tralokinumab however, they show
inconsistent or only modest effects in treating severe asthma
exacerbations in phase 3 clinical trials. Our results are consistent
with IL-13 as a therapeutic target for asthma and suggest the
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potential for improved efficacy if treatment is targeted towards
specific genetic subgroups.
We found strong causal effects of neonatal BTN3A2 expression
on various autoimmune and allergic diseases. Butyrophilin (BTN)
family members are immunoglobulin-like molecules that act as
immune check-point regulators with roles in self-tolerance48.
Increased BTN3A2 protein expression is a favourable prognostic
biomarker in epithelial ovarian cancer patients, and indicates a
higher density of intraepithelial infiltration of T cells49. BTN3
family members BTN3A1 and BTN3A3 are proximal to BTN3A2.
The antigen-presenting BTN3A1 is critical to human γδ T cell
activation50. A recent study showed that BTN3A2 regulated
subcellular localisation of BTN3A1, and both were required for T
cell activation51. Previous MR analysis found BTN3A2 lung
expression had a causal effect on COPD risk52. Our findings
suggest that altered neonatal BTN3A2 expression, with presumed
subsequent dysfunction in immunomodulation, plays a role in the
pathogenesis of multiple inflammatory conditions.
In our study, neonatal HLA-C expression in both myeloid cells
and T cells was causally associated with multiple autoimmune
diseases such as psoriasis, SLE, and primary biliary cirrhosis.
HLA-C encodes an MHC Class I receptor which presents antigens
to CD8+ T cells. It is also the major ligand for killer
immunoglobulin-like receptors (KIRs), which regulate the activity
of natural killer (NK) cells. HLA-C is an established locus for
psoriasis susceptibility53 and the interaction between HLA-C and
ERAP1 is associated with psoriasis risk, where ERAP1 variants
only have psoriasis effects in individuals with the HLA-C risk
allele54. In our analysis of resting neonatal T cells, the largest
causal effect of HLA-C expression was for psoriasis.
Our study had limitations. Cord blood may be under the
influence of in utero exposures (e.g. smoking, drug exposures,
maternal stress) which may confound associations with maternal,
placental or foetal genetics55, and may affect neonatal gene
expression through epigenetic mechanisms56. In utero exposures,
epigenetics, or maternal genetics were not measured in this
cohort. While maternal cells are present in cord blood samples,
the vast majority of cord blood cells are from neonates; previous
estimates of the proportion of maternal cells in cord blood are of
the order of 10−4 to 10−5 of nucleated foetal blood cells57. While
the adherence protocol used in this study can lead to some level of
cell activation, this is also the case with other cell isolation
methods such as MACS, and there is no a priori reason to suspect
that this would deleteriously influence subsequent responsiveness.
Since this is a study in neonates, the blood volumes collected were
necessarily small and mandated the use of micro methods for
in vivo studies where all available material was needed to generate
transcriptional profiles, and ancillary assays, e.g. quantification of
cell purity, were not able to be performed. While RNA-seq
technology allows the identification of additional signals, such as
isoform QTLs, which are relevant in neonatal tissues, it can be
prone to artefacts when constructing large-scale libraries with low
input RNA; therefore, as this neonatal study necessarily relied on
low sample volumes, we consciously chose gene expression arrays
due to their robustness in this setting and well-established nor-
malisation approaches. In silico analyses to infer cell type abun-
dances showed good cell purities (Supplementary Fig. 1), and the
estimated abundances were correlated with the PEER factors
included when mapping eQTLs; thus, while differences in cell
composition may not be completely controlled, we believe these
effects are minimal. Furthermore, we are still relatively power-
limited with regard to trans-eQTL analyses and further studies
with greater sample sizes, particularly in the neonatal and early
childhood settings, are necessary.
In conclusion, our study shows the remarkable complexity of
the genetic regulation of gene expression in the innate and
adaptive arms of the immune system at birth, and its potential
role in the pathogenesis of autoimmunity and allergic disease.
Methods
Study cohort and RNA sample preparation. The study population is a subset of
the CAS, a prospective birth cohort of 234 individuals followed from birth to up to
10 years of age16–18. This project was approved by the University of Western
Australia Human Ethics Committee. Cord blood samples were collected for 152
individuals at birth, and we have obtained informed consent from all participants.
One million peripheral blood mononuclear cells (PBMCs) from each individual
were stimulated with either an innate immune system stimulant (LPS: lipopoly-
saccharide; 25 pg/ml), or a pan T cell stimulant (PHA: phytohemagglutinin; 1 μg/
ml) for 24 h (Fig. 1). Initial stimulation prior to cell enrichment was carried out in
unfractionated PBMCs to enable interactions to occur between myeloid/lymphoid
cells to mimic in vivo conditions in which stimulation events occur in mixed cell
environment. Unstimulated resting PBMC samples were also available. At the end
of the culture period, non-adherent cells in suspension from resting and PHA-
stimulated cultures were aspirated gently and enriched for CD4+ T cells (enriched
T cells) using Dynabeads (Invitrogen) and stored in RNAprotect Cell reagent
(Qiagen). Cells remaining in suspension in resting and LPS-stimulated cultures
were aspirated, leaving an enriched population of monocytes and macrophages
(enriched myeloid cells) adhered to the culture wells, and these were also resus-
pended vigorously into RNAprotect. Cell purities were not experimentally con-
firmed by flow cytometry because of the limited cell numbers available, and instead
as a compromise we employed in silico analysis to estimate the abundances of
relevant cell types from the resultant gene expression data using CIBERSORTx19.
All cells in RNAprotect Cell reagent were banked at −80 °C.
The cells were thawed and centrifuged briefly for RNA extraction. Reagent was
removed and total RNA was extracted from pelleted cells by an established in-
house procedure using TRIzol (Life Technologies) in combination with RNEasy
MinElute columns (Qiagen). The aqueous phase containing the RNA was then
loaded onto an RNeasy MinElute column (Qiagen) to purify and concentrate the
RNA. RNA quality was assessed on a Bioanalyzer 2100 using the RNA 6000 Nano
kit (Agilent). There were 607 samples (one missing sample) in total from 152
individuals for gene expression profiling.
PCA of gene expression data showed the four clusters of samples of different
cell types and conditions (Supplementary Fig. 15). For both deconvolution analysis
(using web-based CIBERSORTx) and PCA, we used gene expression data that were
quantile normalised across all 557 samples that passed QC (see the next section for
the QC and normalisation pipeline), and the plots show the 494 samples from
individuals with genotype data available that were included in the eQTL analysis.
Gene expression profiling and data processing. Total RNA from four cell cul-
ture conditions (resting and LPS-stimulated myeloid cells, and resting and PHA-
stimulated T cells) was quantified with Illumina HumanHT-12 v4 BeadChip gene
expression array at the Genome Institute of Singapore. After excluding 31 samples
with suspected cross-contamination or insufficient quantity of cDNA, 576 samples
were successfully scanned. Supplementary Fig. 16 shows our QC and normalisation
pipeline details. The raw microarray data and probe detection P-values were
exported by the Illumina software GenomeStudio. We first removed three samples
with zero intensity for almost all probes including negative controls and probes
targeting housekeeping genes (two resting myeloid samples and one LPS-
stimulated myeloid sample). We further removed 16 outlier samples (eight resting
myeloid samples, five LPS-stimulated myeloid samples, and three resting T cell
samples) with a low number of detectable probes (lying outside median ±2 × inter
quartile range). Compared with other samples, these excluded samples had much
lower intensity for positive controls including those targeting housekeeping genes.
After quality control, 557 samples remained for normalisation (resting
monocyte/macrophage-enriched cultures: 130, LPS-stimulated monocyte/
macrophage-enriched cultures: 141, resting T-cell-enriched cultures: 142, and
PHA-stimulated T-cell-enriched cultures: 144). We performed background
correction based on the intensity of the 770 negative control probes on the
microarray, and then we performed quantile normalisation and log2
transformation within each cell type and condition using the neqc function from
the limma (v3.36.5) R package58. We used updated probe annotation data and
restricted the analysis to 33,436 reliable probes, excluding unaligned probes and
probes aligned to multiple regions that were more than 25 bp apart59. Fifteen
probes with missing data in ≥5 samples were removed. Detectable probes targeting
autosomal genes (N= 20,532) were kept, comprising of probes with GenomeStudio
detection P-values ≤ 0.01 in ≥2.5% of the samples from a specific condition group,
or in ≥5% of all samples10. Gene annotation was obtained from the GENCODE
release 19 (GRCh37 alignment, downloaded in October 2017). Among detectable
probes, 19,230 had gene annotation in the GENCODE reference data. For genes
that had multiple probes, we kept the probe with the highest mean intensity,
resulting in 13,109 autosomal genes. For eQTL analysis, we performed a rank-
based inverse normal transformation within each group, so that each gene
expression followed a standard normal distribution.
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Genotyping and imputation. Genomic DNA was extracted from blood samples
collected from 218 individuals. Genotyping was performed with Illumina Omni2.5
BeadChip array, with coverage of approximately 2.5 million markers. Variants with
missing call rates >1%, MAF < 1%, or Hardy–Weinberg equilibrium (HWE) test P-
value <1 × 10−6 were excluded, and individuals with missing call rates >1% were
removed using Plink1.9. This produced an initial count of 1.4 million SNPs for 215
genotyped individuals. Of these, a total of 135 children also had gene expression
data from cord blood (i.e. overlap with the 152 individuals described previously),
and 106 and 119 individuals had gene expression data passing QC for both resting
and stimulated conditions of monocyte/macrophage-enriched cultures and T-cell-
enriched cultures, respectively, and 95 individuals had post-QC data for all four
cultures.
We performed genotype imputation using the Michigan Imputation Server60
with Haplotype Reference Consortium (HRC) release r1.1 as the reference panel.
Phasing was performed using Eagle v2.3 and genotype imputation was performed
using Minimac3 v1.0.4. After filtering out variants with low imputation accuracy
(R2 < 0.3), 12.7 million SNPs remained. For eQTL analysis, we focused on 4.3
million SNPs with MAFs ≥ 10%. The MAF cut-off used here was suggested by an
eQTL simulation study in order to avoid inflated false positives in low-frequency
variants given our limited sample size61.
Cis-eQTL mapping and conditional analysis. To identify cis-eQTLs within each
cell type and treatment group, we performed linear additive regression to model the
effect of each SNP located within 1Mb of the transcription start site (TSS) of the
corresponding gene using the Matrix eQTL R package (v2.2)62. The sample size for
eQTL mapping in each experimental condition was: 116 for resting myeloid cells,
125 for LPS-stimulated myeloid cells, 126 for resting T cells, and 127 for PHA-
stimulated T cells. Genotype data were recoded as 0, 1, 2 based on the dosage of the
HRC alternative allele. Gender, first three genotype PCs and first ten PEER63
factors capturing technical variation in transcriptomes were included as covariates
in the linear model.
We applied a hierarchical correction procedure to correct for multiple testing61.
Firstly, nominal P-values for all cis-SNPs from Matrix eQTL were adjusted by
multiplying the number of effective independent SNPs for each gene (local
correction), which was estimated by eigenMT based on genotype correlation
matrix64. Secondly, the minimum locally adjusted P-value for each gene was kept
and the FDR of significant genes was controlled at 5% using the
Benjamini–Hochberg (BH) FDR-controlling procedure (global correction)65.
Genes with global FDR ≤ 0.05 were considered significant eGenes. Thirdly, to
obtain the list of significant eSNPs for each eGene, the locally adjusted minimum
P-value corresponding to the global FDR threshold of 0.05 was calculated, and
SNPs with a locally adjusted P-value lower than the threshold were considered
significant eSNPs.
Next, we performed conditional analyses to identify additional independent
eQTL signals for each eGene. The gene-level P-value nominal thresholds calculated
in the hierarchical multiple-testing correction (eigenMT-BH) were used to
determine significant associations: the locally adjusted minimum P-value
corresponding to the global FDR threshold of 0.05 multiplied by the number of
estimated independent SNPs for each gene. We used a two-step conditional
analysis scheme as follows:
Forward stage. For each eGene, the number of independent cis-eQTL signals was
learnt from an iterative procedure. We started from the top SNP with the mini-
mum P-value for the eGene, which was added as a covariate in the linear model to
test for cis-eQTLs. If any significant SNPs (with P-values smaller than the gene’s
nominal threshold) were identified, the new top SNP identified in this iteration was
added to the list of independent eQTL signals. In the next iteration of eQTL
mapping, all previously identified eSNPs were adjusted for as covariates. The
forward stage terminated if no additional significant associations were identified.
Backward stage. In this stage, the final list of significant SNPs representing each
independent eQTL signal was determined. Let the list of independent SNPs for
each eGene obtained from the forward stage be SNP1; SNP2; SNP3; ¼ ; SNPM ,
where M is the number of independent eQTL signals. Each of the independent
eQTL signals was tested separately using a leave-out-one model adjusting for all
other SNPs in the list as covariates. For example, when the ith eQTL signal was
tested, SNP1; ¼ ; SNPi1; SNPiþ1; ¼ ; SNPM were added as covariates together
with other covariates used in the original eQTL scan. The final set of independent
eQTLs comprised of the eSNPs that remained significant in the backward stage.
For genes that had eQTLs in more than one experimental condition, we also
applied conditional analyses to identify independent eQTL signals between
conditions. More specifically, to determine whether two eQTL signals for an eGene
identified in two experimental conditions were independent or the same signal, we
adjusted for the top eSNP in one condition by adding it as a covariate in the linear
model and performed eQTL scan again in the other condition. If any SNP was
significant in the conditional model using the P-value threshold determined by the
hierarchical correction procedure (eigenMT-BH), we considered these two eQTLs
as independent signals. If none were significant in the conditional model, we
considered it as shared eQTL signal between two conditions or lack of power to
detect the independent signal.
Comparison of neonatal vs adult cis-eQTLs. We downloaded full summary
statistics of cis-eQTL analysis in adults from a response eQTL study in monocytes
(Kim-Hellmuth et al. study11) and from the eQTL analysis in naïve T cells from the
BLUERPRINT project22. Kim-Hellmuth et al. mapped cis-eQTLs in resting and
LPS-stimulated CD14+monocytes with two different durations of LPS: 90 min and
6 h, which were obtained from 134 adults aged from 18 to 35 years11. Chen et al.
mapped cis-eQTLs in naïve CD4+ T cells from 169 adults (mean age of 55 years)
from the BLUEPRINT project22. We could not find full summary statistics of any
response eQTL analyses in stimulated T cells, so we only compared eQTLs in
resting T cells.
To identify myeloid eQTLs that were specific to neonates, we analysed gene-
SNP pairs (involving 10,749 genes) that had summary statistics available in both
our study and the Kim-Hellmuth et al. study using the mashr (v0.2.21) R
package20. Z scores were used as input. We used the most significant SNP for each
gene as the strong set to learn data-driven covariance matrices, and randomly
selected around nine tests for each gene as the random set to learn correlation
structure among null tests and to fit the mash model. Posterior summaries were
calculated for top eSNPs of each eGene using the fitted mash model, and calculated
the local false sign rate (LFSR) for the most significant SNPs of 105 (out of 136)
and 332 (out of 376) eGenes in resting and LPS-stimulated myeloid cells,
respectively. Summary statistics for tests involving 7501 genes were available in
both our study and the BLUEPRINT project, and we tested the most significant
SNPs of 639 out of 971 eGenes identified in resting T cells. Neonate-specific eQTLs
were defined as eQTLs that had LFDR < 0.05 in our dataset but not in cells from
adults.
We have also estimated the sharing of cis-eQTLs between neonates and adults
using the Storey and Tibshirani q-value approach23. π1 statistic was calculated to
quantify the replication rate using the qvalue (v2.16.0) R package. We used the
pi0est function to estimate the proportion of tests that were truly null (π0) among a
list of P-values, given the assumption that P-values of truly null hypotheses should
follow a uniform distribution. The proportion of true positive π1 was calculated as
1 π0. To estimate the sharing of eQTLs between two datasets, we focused on
significant eQTL associations identified in one dataset, and used the corresponding
P-values of the same list of tests (SNP-gene pairs) from the second dataset as input
of the pi0est function.
Enrichment analysis. We performed enrichment analyses using GARFIELD
(version 2) to investigate the enrichment patterns of cis-eQTLs using predefined
features such as genic annotations from ENCODE, GENCODE, and Roadmap
Epigenomics project provided by this tool21. GARFIELD evaluates enrichment
using generalised linear regression models that account for allele frequency, dis-
tance to the nearest gene TSS, and LD. LD correlation based on the UK10K dataset
is also provided by the software. In each experimental condition, we used P-values
for all SNPs tested in cis-eQTL analysis. If a SNP was tested for association with
multiple genes, the smallest P-value was kept. Enrichment odds ratios were cal-
culated at various eQTL significance thresholds: 1 × 10−3, 1 × 10−4, …, 1 × 10−7
(Supplementary Fig. 4), because GARFIELD accepts one single threshold.
Response eQTL detection. Response eQTLs (reQTLs) were identified in myeloid
cells and T cells separately. For each cell type, we focused on top eSNPs of eGenes
that were significant in either resting or stimulated conditions. For eGenes that
were significant in both conditions and for which two top eSNPs were not in high
LD (r2 < 0.8), we tested both of the top eSNPs; on the other hand, if the two top
eSNPs were in high LD, we tested the more significant one, to reduce tests on
redundant SNPs. In myeloid cells, 417 interaction tests involving 398 eGenes were
performed, and 1959 tests involving 1749 eGenes were performed in T cells. Gene
expression data in two conditions were combined within each cell type, and the
following linear mixed-effects model was tested for eGene–top eSNP pairs using
the lmer function in the lme4 R package (v1.1-18-1)66:
yi  xi þ ci þ xi ´ ci þ x1i þ ¼ þ x14i þ x1i ´ ci þ ¼ þ x14i ´ ci þ ð1 Sij Þ: ð1Þ
where yi indicates the expression level of an eGene for the i
th sample, xi the SNP
allele dosage, ci the condition (resting: 0 and stimulated: 1) in which the gene
expression was measured, x1i ; ¼ x
14
i . the 14 covariates used in the original eQTL
mapping (gender, three genotype PCs, and ten PEER factors), and Si the individual
from which the ith sample was taken. The term xi ´ ci models the interaction
between the genotype and the condition, and 1 Sijð Þ indicates the individual-specific
random effect for this paired study design.
We applied permutations to estimate empirical P-values for the interaction
term. In each permutation step, the condition variable was shuffled within each
individual, and the same linear mixed model was tested to get the permuted
statistics for the interaction term12,67. The permutation-determined P-value for
each interaction test was calculated as (s+ 1)/(n+ 1), where n was the total
number of permutations (1000) and s was the number of cases where the
permutated statistics were more significant than the original observed ones. We
added 1 to both the numerator a the denominator to avoid underestimating
permutation P-values. BH FDR-controlling procedure was applied to the
permutation P-values and significant interactions were identified at 5% FDR.
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Trans-eQTL identification. To detect trans-acting genetic regulation of gene
expression in each condition, we tested for associations between SNPs and genes
that were located on different chromosomes using the same linear model and
covariates as in the cis-eQTL mapping. We tried the following different approaches
to deal with the multiple testing:
Genome-wide FDR correction. BH FDR-controlling procedure was applied to
nominal P-values from all trans-association tests, and significant trans-associations
were identified at 5% FDR6.
Gene-level FDR correction. For each gene, the P-value of the top SNP was multi-
plied by 1 × 106, which was the estimated number of independent SNPs across the
genome (calculated as 0.05 divided by the commonly used genome-wide sig-
nificance threshold of 5 × 10−8). To control gene-level FDR, a BH FDR-controlling
procedure was then applied to the minimum adjusted P-values for all genes.
Gene-level Bonferroni correction. Bonferroni correction was used to control the
gene-level FDR, by using a significance P-value threshold of 3.8 × 10−12 (5 × 10−8/
13,109, where the denominator indicates the number of genes). The Bonferroni
correction was extremely conservative because the tests (or genes) were not
independent with each other.
In resting myeloid cells as well as in LPS-stimulated myeloid cells, one trans-
eQTL signal was significant in all three methods. At 5% genome-wide FDR level,
we observed 10 and 15 eGenes with significant trans-eQTLs (trans-eGenes) in
resting and PHA-stimulated T cells, respectively, corresponding to a nominal P-
value threshold of 1.9 × 10−10 in resting T cells and 2.5 × 10−10 in PHA-treated
T cells. The number of significant trans-eGenes dropped, respectively, to six and
eight by using the gene-level FDR correction (corresponding to a nominal P-value
threshold of 5.3 × 10−12 in both conditions), and to five and seven by using the
gene-level Bonferroni correction. The limited power was the major issue given the
sample size; thus, we used genome-wide FDR correction, the least conservative
method, to determine significant trans-eQTLs used in the downstream analysis6.
Mediation analysis. We hypothesised that trans-eQTLs regulated the expression
of distant genes through cis-mediators, or local genes whose expression was
regulated by the same trans-eQTLs. To test this hypothesis, we focused on the
trans-eQTLs that were also associated with adjacent cis-eGenes, meaning that the
trans-eQTLs were also cis-eQTLs. For each trans-eGene–cis-eGene pair, we tested
the trans-eSNP with the smallest P-value as the exposure, a cis-eGene as the
mediator, and a trans-eGene as the outcome (Fig. 3b). In total, we tested 14
mediation trios: one from resting myeloid cells, one from LPS-stimulated myeloid
cells, nine from resting T cells, and three from PHA-stimulated T cells.
We performed mediation test for the 14 trios using the mediation R package
(v4.4.6)68. The effect of the exposure on the mediator (a) was estimated in cis-
eQTL mapping. The effect of the mediator on the outcome (b) adjusting for the
exposure and the effect of the exposure on the outcome (c0) adjusting for the
mediator were estimated in the following multiple regression:
yi  xi þ xcisi þ x1i þ ¼ þ x14i : ð2Þ
where yi indicates the value of the outcome (or the expression level of the trans-
eGene) for the ith sample, xi the exposure (or the eSNP allele dosage), x
cis
i the
mediator (or the cis-eGene expression), and x1i ; ¼ x
14
i the 14 covariates used in
eQTL mapping. The estimates of b and c0 were beta coefficients for xcisi and xi ,
respectively. The direct effect of the exposure on the outcome was quantified as c0,
the indirect effect of the exposure on the outcome through the mediator was
quantified as a ´ b, and the total effect was the sum of the previous two effects.
Complete mediation occurs when the direct effect c0 is zero after controlling for the
mediator, and partial mediation happens when the direct effect is different from
zero. To identify significant mediation trios (the null hypothesis H0 : ab ¼ 0), we
used a nonparametric bootstrap method (10,000 simulations) implemented in the
mediation R package for variance estimation and P-value calculation. BH FDR-
controlling procedure was applied to correct for multiple testing.
Genetic overlap of eQTLs and diseases. We downloaded publicly-available
GWAS data for the following immune-mediated diseases: allergic disease (asthma,
hay fever, or eczema), allergic rhinitis, allergic sensitisation, asthma (childhood-
onset and adult-onset asthma), inflammatory bowel disease including its two
subtypes—Crohn’s disease and ulcerative colitis, celiac disease, autoimmune
thyroid disease, juvenile idiopathic arthritis, multiple sclerosis, narcolepsy, primary
biliary cirrhosis, primary sclerosing cholangitis, psoriasis, rheumatoid arthritis,
systemic lupus erythematosus, and type 1 diabetes. We also analysed the summary
statistics from a GWAS of educational attainment as a negative control. References
of the GWAS studies are in Supplementary Information. These datasets contained
summary statistics obtained using European populations for both significant and
non-significant genetic variants, and GRCh37 genomic coordinates were available.
We performed enrichment tests for each of the four sets of significant eQTLs
using GARFIELD21. Generalised linear models were applied to test for enrichment
in eQTLs of variants associated with the above diseases at a significance threshold
of 1 × 10−6. Bonferroni correction was applied to correct for multiple testing,
where the number of tests was the number of GWAS datasets (24) multiplied by
the number of eQTL datasets (4), and the Bonferroni-adjusted P-value threshold
was 5.0 × 10−4, adjusting for the 4 × 25 (100) tests.
Colocalisation of cis-eQTLs with disease associations. We applied a Bayesian
method implemented in the coloc R package (v3.1)25 to test whether any of the
disease-associated GWAS loci shared the same causal variants with the cis-eQTLs.
Full summary statistics were required to run the colocalisation analysis using coloc.
For loci where cis-eQTLs were also associated with diseases at a P-value threshold
of 1 × 10−6, colocalisation test was performed on a 400-kb window centered on the
top cis-eSNP. For each locus, colocalisation test was performed on overlapping
SNPs where both eQTL and GWAS summary statistics were available. We
excluded regions where not enough SNPs (<25) were available for colocalisation
test. Selection of different prior probabilities of a SNP being causal for both of the
traits affects the posterior support for colocalisation. To be conservative, we used a
lower prior probability of 1 × 10−6 instead of the default value of 1 × 10−5.
For each locus, the Bayesian method assessed the support for the following five
exclusive hypotheses: no causal variants for either of the two traits (H0), a causal
variant for gene expression only (H1), a causal variant for disease risk only (H2),
distinct causal variants for two traits (H3), and the same shared causal variant for
both traits (H4). The package estimated posterior probabilities (PP0, PP1, PP2, PP3,
PP4) to summarise the evidence for the above five hypotheses. High PP1 or PP2 and
low PP3+ PP4 indicate a lack of power to identify the causal signals25. We excluded
loci where PP3+ PP4 < 0.8, and focused on loci with strong evidence support for
shared causal variants (H4), i.e. ratio of PP4 to PP3 ≥ 5.
To assess if our significant colocalisations were robust across a range of different
p12 priors (from 1 × 10−9 to 1 × 10−5), we performed the sensitivity analysis using
the sensitivity function in a newer version of the coloc R package (v4.0). All our
significant colocalisations passed the sensitivity analysis, and PP4 values using
different priors can be found in Supplementary Data 4.
Mendelian randomisation analysis. To investigate causal effects of eGene
expression on the above immune-mediated diseases, we performed a two-sample
Mendelian randomisation (MR) analysis. Summary statistics from both our eQTL
and external GWAS studies were required, including beta coefficient and its
standard error, effective allele (based on which the beta was estimated), the other
allele, and P-value. For each disease trait, we used cis-eSNPs that were also included
in the GWAS dataset, and removed ambiguous variants (if any) using the Two-
SampleMR R package (v0.4.14)69. We then selected LD pruned (r2 < 0.1) cis-eSNPs
as genetic instrumental variables (IVs). We focused on eGenes with at least three
genetic IVs available, and performed the following MR methods implemented in
the MendelianRandomization R package (v0.4.1)70: inverse variance weighted
(IVW), weighted median, weighted mode, and MR Egger. These methods have
different assumptions for valid IVs: IVW assumes that all IVs are valid; weighted
median assumes that valid IVs contribute to more than 50% of the weight;
weighted mode assumes that the largest group of IVs are valid; MR Egger
regression, which is the least sensitive, assumes that the pleiotropic effects of IVs
are not correlated with the genetic effects on exposure. We excluded the causal
associations for which the intercept in the MR Egger method was significantly not
equal to 0, indicating significant average pleiotropic effects. Gene expression was
considered to have suggestive evidence of causal effects when at least three out of
the four methods provided significant P-value (≤0.05). In the ‘Results’ section, we
reported the statistics of the weighted mode method, which has the least
assumption among all methods except the MR Egger, but is more sensitive than
MR Egger.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw microarray data, normalised gene expression data, and full summary statistics of
the eQTL and response eQTL analyses have been deposited in ArrayExpress with the
accession code E-MTAB-8977. GWAS summary statistics used in this study are from the
following publicly available sources: ImmunoBase (https://www.immunobase.org/), LD
Hub (http://ldsc.broadinstitute.org/ldhub/), and GWAS Catalog (https://www.ebi.ac.uk/
gwas/). The transcriptome profiles used to infer cell type abundances (CIBERSORTx) are
available on https://cibersortx.stanford.edu. The GENCODE reference data are available
at https://www.gencodegenes.org. The Haplotype Reference Consortium (HRC) r1.1
imputation reference panel was available at https://imputationserver.sph.umich.edu/.
Code availability
The analysis scripts for eQTL mapping, colocalisation, and Mendelian Randomisation
are available at https://github.com/QinqinHuang/CAS_eQTL.
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